The Mechanism of Carvedilol in Experimental Viral Myocarditis

Author(s): Li Yue-Chun, Ge Li-Sha, Guan Xue-Qiang, Lin Jia-Feng

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 12 , 2012

Become EABM
Become Reviewer
Call for Editor


Carvedilol is a nonselective β-blocker with α1-adrenergic blocking and antioxidant properties. A number of preclinical experiments and clinical trials have demonstrated that carvedilol provides prominent benefit in heart failure. However, less research has been done in the area of animal models of viral myocarditis. This paper reviews the use of carvedilol in animal models of viral myocarditis. The experimental evidence strongly suggests that carvedilol, but not metoprolol (a selective β1-adrenergic blocking agent), protects against viral myocarditis and the superior cardioprotection effect of carvedilol to metoprolol may be due to its upregulating the production of antiinflammatory cytokines, downregulating the production of proinflammatory cytokines, antioxidative effects, the suppression of matrix metalloproteinases production, and positive hemodynamic effects.

Keywords: Carvedilol, viral myocarditis, cytokines, antioxidants, hemodynamics, nonselective -blocker, heart failure, metoprolol, matrix metalloproteinases production, viral injury

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 23 April, 2012
Page: [1620 - 1624]
Pages: 5
DOI: 10.2174/138161212799958530
Price: $65

Article Metrics

PDF: 14